$REGN REGENERON PHARMACEUTICALS, INC. Insider Trading Week 16/2020
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in REGENERON PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in REGENERON PHARMACEUTICALS, INC. in week 16/2020.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 12,500 | 3,408,750 | 19,000 | |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 4,000 | 1,090,800 | 31,500 | |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 573.40 | 320 | 183,488 | 24,373 | 24.7 K to 24.4 K (-1.30 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 572.42 | 64 | 36,635 | 24,693 | 24.8 K to 24.7 K (-0.26 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 571.65 | 114 | 65,168 | 24,757 | 24.9 K to 24.8 K (-0.46 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 569.22 | 66 | 37,569 | 24,871 | 24.9 K to 24.9 K (-0.26 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 568.11 | 126 | 71,582 | 24,937 | 25.1 K to 24.9 K (-0.50 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 567.76 | 114 | 64,725 | 25,063 | 25.2 K to 25.1 K (-0.45 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 566.44 | 944 | 534,719 | 25,177 | 26.1 K to 25.2 K (-3.61 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 565.52 | 902 | 510,099 | 26,121 | 27 K to 26.1 K (-3.34 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 564.76 | 340 | 192,018 | 27,023 | 27.4 K to 27 K (-1.24 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 563.74 | 225 | 126,842 | 27,363 | 27.6 K to 27.4 K (-0.82 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 562.71 | 35 | 19,695 | 27,588 | 27.6 K to 27.6 K (-0.13 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 12,500 | 3,408,750 | 19,000 | |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 555.82 | 9,250 | 5,141,335 | 27,623 | 36.9 K to 27.6 K (-25.09 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 4,000 | 1,090,800 | 31,500 | |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 12,500 | 3,408,750 | 36,873 | 24.4 K to 36.9 K (+51.29 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 573.40 | 320 | 183,488 | 24,373 | 24.7 K to 24.4 K (-1.30 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 565.77 | 44 | 24,894 | 24,373 | 24.4 K to 24.4 K (-0.18 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 572.42 | 64 | 36,635 | 24,693 | 24.8 K to 24.7 K (-0.26 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 563.63 | 66 | 37,200 | 24,417 | 24.5 K to 24.4 K (-0.27 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 571.65 | 114 | 65,168 | 24,757 | 24.9 K to 24.8 K (-0.46 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 562.77 | 33 | 18,571 | 24,483 | 24.5 K to 24.5 K (-0.13 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 569.22 | 66 | 37,569 | 24,871 | 24.9 K to 24.9 K (-0.26 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 561.96 | 92 | 51,700 | 24,516 | 24.6 K to 24.5 K (-0.37 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 568.11 | 126 | 71,582 | 24,937 | 25.1 K to 24.9 K (-0.50 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 560.31 | 232 | 129,992 | 24,608 | 24.8 K to 24.6 K (-0.93 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 567.76 | 114 | 64,725 | 25,063 | 25.2 K to 25.1 K (-0.45 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 559.25 | 155 | 86,684 | 24,840 | 25 K to 24.8 K (-0.62 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 566.44 | 944 | 534,719 | 25,177 | 26.1 K to 25.2 K (-3.61 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 558.63 | 89 | 49,718 | 24,995 | 25.1 K to 25 K (-0.35 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 565.52 | 902 | 510,099 | 26,121 | 27 K to 26.1 K (-3.34 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 556.43 | 33 | 18,362 | 25,084 | 25.1 K to 25.1 K (-0.13 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 564.76 | 340 | 192,018 | 27,023 | 27.4 K to 27 K (-1.24 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 553.85 | 62 | 34,339 | 25,117 | 25.2 K to 25.1 K (-0.25 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 563.74 | 225 | 126,842 | 27,363 | 27.6 K to 27.4 K (-0.82 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 551.38 | 55 | 30,326 | 25,179 | 25.2 K to 25.2 K (-0.22 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 562.71 | 35 | 19,695 | 27,588 | 27.6 K to 27.6 K (-0.13 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 550.00 | 3 | 1,650 | 25,234 | 25.2 K to 25.2 K (-0.01 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 555.82 | 9,250 | 5,141,335 | 27,623 | 36.9 K to 27.6 K (-25.09 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 548.99 | 61 | 33,488 | 25,237 | 25.3 K to 25.2 K (-0.24 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 12,500 | 3,408,750 | 36,873 | 24.4 K to 36.9 K (+51.29 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 542.25 | 33 | 17,894 | 25,298 | 25.3 K to 25.3 K (-0.13 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 565.77 | 44 | 24,894 | 24,373 | 24.4 K to 24.4 K (-0.18 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 540.70 | 33 | 17,843 | 25,331 | 25.4 K to 25.3 K (-0.13 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 563.63 | 66 | 37,200 | 24,417 | 24.5 K to 24.4 K (-0.27 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 529.79 | 3,009 | 1,594,138 | 25,364 | 28.4 K to 25.4 K (-10.61 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 562.77 | 33 | 18,571 | 24,483 | 24.5 K to 24.5 K (-0.13 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 4,000 | 1,090,800 | 28,373 | 24.4 K to 28.4 K (+16.41 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 561.96 | 92 | 51,700 | 24,516 | 24.6 K to 24.5 K (-0.37 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 560.31 | 232 | 129,992 | 24,608 | 24.8 K to 24.6 K (-0.93 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 5,000 | 296,000 | 18,311 | |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 559.25 | 155 | 86,684 | 24,840 | 25 K to 24.8 K (-0.62 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 6,622 | 392,022 | 23,311 | |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 558.63 | 89 | 49,718 | 24,995 | 25.1 K to 25 K (-0.35 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 5,000 | 296,000 | 29,933 | |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 556.43 | 33 | 18,362 | 25,084 | 25.1 K to 25.1 K (-0.13 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 573.59 | 577 | 330,961 | 14,438 | 15 K to 14.4 K (-3.84 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 553.85 | 62 | 34,339 | 25,117 | 25.2 K to 25.1 K (-0.25 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 572.94 | 61 | 34,949 | 15,015 | 15.1 K to 15 K (-0.40 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 551.38 | 55 | 30,326 | 25,179 | 25.2 K to 25.2 K (-0.22 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 571.65 | 112 | 64,025 | 15,076 | 15.2 K to 15.1 K (-0.74 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 550.00 | 3 | 1,650 | 25,234 | 25.2 K to 25.2 K (-0.01 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 570.27 | 125 | 71,284 | 15,188 | 15.3 K to 15.2 K (-0.82 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 548.99 | 61 | 33,488 | 25,237 | 25.3 K to 25.2 K (-0.24 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 569.41 | 234 | 133,242 | 15,313 | 15.5 K to 15.3 K (-1.51 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 542.25 | 33 | 17,894 | 25,298 | 25.3 K to 25.3 K (-0.13 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 567.30 | 669 | 379,524 | 15,547 | 16.2 K to 15.5 K (-4.13 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 540.70 | 33 | 17,843 | 25,331 | 25.4 K to 25.3 K (-0.13 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 566.44 | 1,189 | 673,497 | 16,216 | 17.4 K to 16.2 K (-6.83 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 529.79 | 3,009 | 1,594,138 | 25,364 | 28.4 K to 25.4 K (-10.61 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 565.60 | 1,468 | 830,301 | 17,405 | 18.9 K to 17.4 K (-7.78 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 4,000 | 1,090,800 | 28,373 | 24.4 K to 28.4 K (+16.41 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 564.74 | 377 | 212,907 | 18,873 | 19.3 K to 18.9 K (-1.96 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 563.58 | 416 | 234,449 | 19,250 | 19.7 K to 19.3 K (-2.12 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 562.71 | 21 | 11,817 | 19,666 | 19.7 K to 19.7 K (-0.11 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 561.57 | 51 | 28,640 | 19,687 | 19.7 K to 19.7 K (-0.26 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 5,000 | 296,000 | 18,311 | |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 555.82 | 2,720 | 1,511,830 | 19,738 | 22.5 K to 19.7 K (-12.11 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 6,622 | 392,022 | 23,311 | |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 59.20 | 5,000 | 296,000 | 22,458 | 17.5 K to 22.5 K (+28.64 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 5,000 | 296,000 | 29,933 | |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 555.82 | 3,602 | 2,002,064 | 17,458 | 21.1 K to 17.5 K (-17.10 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 573.59 | 577 | 330,961 | 14,438 | 15 K to 14.4 K (-3.84 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 59.20 | 6,622 | 392,022 | 21,060 | 14.4 K to 21.1 K (+45.87 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 572.94 | 61 | 34,949 | 15,015 | 15.1 K to 15 K (-0.40 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 565.92 | 94 | 53,196 | 14,438 | 14.5 K to 14.4 K (-0.65 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 571.65 | 112 | 64,025 | 15,076 | 15.2 K to 15.1 K (-0.74 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 564.19 | 93 | 52,470 | 14,532 | 14.6 K to 14.5 K (-0.64 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 570.27 | 125 | 71,284 | 15,188 | 15.3 K to 15.2 K (-0.82 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 563.39 | 171 | 96,340 | 14,625 | 14.8 K to 14.6 K (-1.16 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 569.41 | 234 | 133,242 | 15,313 | 15.5 K to 15.3 K (-1.51 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 562.56 | 191 | 107,449 | 14,796 | 15 K to 14.8 K (-1.27 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 567.30 | 669 | 379,524 | 15,547 | 16.2 K to 15.5 K (-4.13 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 561.76 | 63 | 35,391 | 14,987 | 15.1 K to 15 K (-0.42 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 566.44 | 1,189 | 673,497 | 16,216 | 17.4 K to 16.2 K (-6.83 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 560.38 | 163 | 91,342 | 15,050 | 15.2 K to 15.1 K (-1.07 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 565.60 | 1,468 | 830,301 | 17,405 | 18.9 K to 17.4 K (-7.78 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 559.79 | 285 | 159,540 | 15,213 | 15.5 K to 15.2 K (-1.84 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 564.74 | 377 | 212,907 | 18,873 | 19.3 K to 18.9 K (-1.96 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 558.55 | 293 | 163,655 | 15,498 | 15.8 K to 15.5 K (-1.86 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 563.58 | 416 | 234,449 | 19,250 | 19.7 K to 19.3 K (-2.12 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 557.40 | 93 | 51,838 | 15,791 | 15.9 K to 15.8 K (-0.59 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 562.71 | 21 | 11,817 | 19,666 | 19.7 K to 19.7 K (-0.11 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 556.51 | 198 | 110,189 | 15,884 | 16.1 K to 15.9 K (-1.23 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 561.57 | 51 | 28,640 | 19,687 | 19.7 K to 19.7 K (-0.26 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 555.10 | 114 | 63,281 | 16,082 | 16.2 K to 16.1 K (-0.70 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 555.82 | 2,720 | 1,511,830 | 19,738 | 22.5 K to 19.7 K (-12.11 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 552.85 | 104 | 57,496 | 16,196 | 16.3 K to 16.2 K (-0.64 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 59.20 | 5,000 | 296,000 | 22,458 | 17.5 K to 22.5 K (+28.64 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 550.00 | 6 | 3,300 | 16,300 | 16.3 K to 16.3 K (-0.04 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 555.82 | 3,602 | 2,002,064 | 17,458 | 21.1 K to 17.5 K (-17.10 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 549.24 | 100 | 54,924 | 16,306 | 16.4 K to 16.3 K (-0.61 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 59.20 | 6,622 | 392,022 | 21,060 | 14.4 K to 21.1 K (+45.87 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 548.27 | 99 | 54,279 | 16,406 | 16.5 K to 16.4 K (-0.60 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 565.92 | 94 | 53,196 | 14,438 | 14.5 K to 14.4 K (-0.65 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 547.00 | 100 | 54,700 | 16,505 | 16.6 K to 16.5 K (-0.60 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 564.19 | 93 | 52,470 | 14,532 | 14.6 K to 14.5 K (-0.64 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 542.31 | 5 | 2,712 | 16,605 | 16.6 K to 16.6 K (-0.03 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 563.39 | 171 | 96,340 | 14,625 | 14.8 K to 14.6 K (-1.16 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 541.94 | 95 | 51,484 | 16,610 | 16.7 K to 16.6 K (-0.57 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 562.56 | 191 | 107,449 | 14,796 | 15 K to 14.8 K (-1.27 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 529.79 | 2,733 | 1,447,916 | 16,705 | 19.4 K to 16.7 K (-14.06 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 561.76 | 63 | 35,391 | 14,987 | 15.1 K to 15 K (-0.42 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 59.20 | 5,000 | 296,000 | 19,438 | 14.4 K to 19.4 K (+34.63 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 560.38 | 163 | 91,342 | 15,050 | 15.2 K to 15.1 K (-1.07 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 559.79 | 285 | 159,540 | 15,213 | 15.5 K to 15.2 K (-1.84 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 558.55 | 293 | 163,655 | 15,498 | 15.8 K to 15.5 K (-1.86 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 557.40 | 93 | 51,838 | 15,791 | 15.9 K to 15.8 K (-0.59 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 556.51 | 198 | 110,189 | 15,884 | 16.1 K to 15.9 K (-1.23 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 555.10 | 114 | 63,281 | 16,082 | 16.2 K to 16.1 K (-0.70 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 552.85 | 104 | 57,496 | 16,196 | 16.3 K to 16.2 K (-0.64 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 550.00 | 6 | 3,300 | 16,300 | 16.3 K to 16.3 K (-0.04 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 549.24 | 100 | 54,924 | 16,306 | 16.4 K to 16.3 K (-0.61 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 548.27 | 99 | 54,279 | 16,406 | 16.5 K to 16.4 K (-0.60 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 547.00 | 100 | 54,700 | 16,505 | 16.6 K to 16.5 K (-0.60 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 542.31 | 5 | 2,712 | 16,605 | 16.6 K to 16.6 K (-0.03 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 541.94 | 95 | 51,484 | 16,610 | 16.7 K to 16.6 K (-0.57 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 529.79 | 2,733 | 1,447,916 | 16,705 | 19.4 K to 16.7 K (-14.06 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 59.20 | 5,000 | 296,000 | 19,438 | 14.4 K to 19.4 K (+34.63 %) |